EP042/#209  Clptm1l expression predicts recurrence of intermediate- and high-risk stage IB-IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy

IntroductionWe examined the correlation between CLPTM1L (Cleft lip and palate transmembrane protein 1-like) expression and recurrence of intermediate- and high-risk stage IB-IIB (FIGO2008) cervical cancer undergoing radical hysterectomy followed by TP (paclitaxel plus cisplatin).MethodsWe reviewed 9...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 33; no. Suppl 4; p. A98
Main Authors Awazu, Yuichiro, Fukuda, Takeshi, Noda, Takuya, Uchikura, Eijiro, Nanno, Shigenori, Imai, Kenji, Wada, Takuma, Yamauchi, Makoto, Yasui, Tomoyo, Sumi, Toshiyuki
Format Journal Article
LanguageEnglish
Published Oxford BMJ Publishing Group Ltd 07.11.2023
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IntroductionWe examined the correlation between CLPTM1L (Cleft lip and palate transmembrane protein 1-like) expression and recurrence of intermediate- and high-risk stage IB-IIB (FIGO2008) cervical cancer undergoing radical hysterectomy followed by TP (paclitaxel plus cisplatin).MethodsWe reviewed 91 cases of intermediate- and high-risk stage IB-IIB cervical cancer patients who underwent TP after radical hysterectomy from 2014 to 2019. Cases were divided into two groups, one group in which the patients didn’t recur within 2 years after initialization of treatment (group A; n=76), and the other group in which the patients recurred within 2 years (group B; n=15). CLPTM1L expression was examined immunohistochemically. Multiple logistic regression analysis was performed to identify predictor of recurrence. The effect of the siRNA-mediated knockdown of CLPTM1L on the sensitivity of cervical cancer cells to cisplatin was investigated. This study was approved by the institutional review board.ResultsThe expression of CLPTM1L was significantly higher in group B than in group A (p<0.001). Cases were divided into two groups; low CLPTM1L expression group (weighted score≤4, n=59), and high CLPTM1L expression group (weighted score≥6, n=32). High CLPTM1L expression group was more likely to recur after adjuvant TP than low expression group (p<0.01). And multivariant analysis revealed that CLPTM1lL expression was an independent predictor of recurrence (P=0.003). Furthermore, knockdown of CLPTM1L expression significantly increased cancer cell sensitivity to cisplatin in vitro.Conclusion/ImplicationsHigh CLPTM1L expression might be associated with recurrence of intermediate- and high-risk stage IB-IIB cervical cancer undergoing radical hysterectomy followed by TP.
Bibliography:IGCS 2023 Annual Meeting Abstracts
AS03. Cervical cancer
ISSN:1048-891X
1525-1438
DOI:10.1136/ijgc-2023-IGCS.163